1y return+209.5%S&P 500 +20.9%
3y return+242.3%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2022: $357 against $195 in the S&P 500.2
Venrock Adviser, LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| Apogee Therapeutics IncCUSIP 03770N101 | $1.1B | 34.2% | |
| ORKAOruka Therapeutics Inc | $394.8M | 12.0% | |
| ERASErasca Inc | $327.8M | 9.9% | +9.2% |
| SYRESpyre Therapeutics Inc | $265.0M | 8.0% | −19.0% |
| DNTHDianthus Therapeutics Inc | $115.0M | 3.5% | |
| OCULOcular Therapeutix Inc | $101.6M | 3.1% | |
| Damora Therapeutics IncCUSIP 36322Q206 | $93.7M | 2.8% | |
| SVRASavara Inc | $90.8M | 2.8% | +7.3% |
| JBIOJade Biosciences Inc | $71.6M | 2.2% | |
| COGTCogent Biosciences Inc | $63.6M | 1.9% | −17.9% |
| VRDNViridian Therapeutics Inc | $59.8M | 1.8% | −16.1% |
| VORVor Biopharma Inc | $56.0M | 1.7% | |
| DYNDyne Therapeutics Inc | $48.3M | 1.5% | |
| MAZEMaze Therapeutics Inc | $47.8M | 1.4% | |
| RLMDRelmada Therapeutics Inc | $47.4M | 1.4% | +41.3% |
| ORICOric Pharmaceuticals Inc | $46.8M | 1.4% | |
| Crescent Biopharma Inc.CUSIP G2545C104 | $38.4M | 1.2% | |
| Zura Bio LtdCUSIP G9TY5A101 | $38.0M | 1.2% | |
| ANLAdlai Nortye Ltd | $36.9M | 1.1% | |
| ELVNEnliven Therapeutics Inc | $26.7M | 0.8% | −69.5% |
| Cybin IncCUSIP 23256X407 | $25.5M | 0.8% | |
| CGEMCullinan Therapeutics Inc | $25.1M | 0.8% | |
| IPSCCentury Therapeutics Inc | $21.3M | 0.6% | |
| ARTVArtiva Biotherapeutics Inc | $19.8M | 0.6% | +27.0% |
| CTMXCytomx Therapeutics Inc | $18.7M | 0.6% | −50.1% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| DNTHDianthus Therapeutics Inc | September 30, 2023 | +613.1% | $115.0M |
| Apogee Therapeutics IncCUSIP 03770N101 | September 30, 2023 | +523.1% | $1.1B |
| SYRESpyre Therapeutics Inc | December 31, 2023 | +312.5% | $265.0M |
| ORKAOruka Therapeutics Inc | September 30, 2024 | +288.3% | $394.8M |
| COGTCogent Biosciences Inc | December 31, 2020 | +244.6% | $63.6M |
| ELVNEnliven Therapeutics Inc | March 31, 2023 | +131.7% | $26.7M |
| SRZNSurrozen Inc | March 31, 2025 | +122.6% | $16.4M |
| JBIOJade Biosciences Inc | June 30, 2025 | +122.4% | $71.6M |
| SVRASavara Inc | March 31, 2025 | +122.4% | $90.8M |
| OCULOcular Therapeutix Inc | December 31, 2023 | +120.2% | $101.6M |
Sold off last quarter
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $130.3M
- Engene Holdings IncCUSIP 29286M105 was $32.5M
- TENXTenax Therapeutics Inc was $26.8M
- SEPNSepterna Inc was $12.2M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +35.5% | +14.8% |
| March 31, 2026 | +16.1% | −4.6% |
| December 31, 2025 | +54.6% | +2.4% |
| September 30, 2025 | +27.3% | +7.8% |
| June 30, 2025 | +12.2% | +10.5% |
| March 31, 2025 | −24.3% | −4.6% |
| December 31, 2024 | −18.9% | +2.1% |
| September 30, 2024 | +19.0% | +5.4% |
| June 30, 2024 | −24.7% | +4.0% |
| March 31, 2024 | +53.8% | +10.0% |
| December 31, 2023 | +35.3% | +11.2% |
| September 30, 2023 | −14.0% | −3.6% |
| June 30, 2023 | +14.7% | +8.3% |
| March 31, 2023 | −9.0% | +7.0% |
| September 30, 2022 | +23.4% | −5.3% |
| June 30, 2022 | −25.2% | −16.5% |
| March 31, 2022 | −18.3% | −4.9% |
| December 31, 2021 | −15.7% | +10.7% |
| September 30, 2021 | −6.4% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Venrock Adviser, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1615982&type=13F-HR&dateb=&owner=include&count=40CIK 1615982
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1615982/000161598226000015/Filed August 14, 2026 · accession 0001615982-26-000015